1. 92% of iNHL patients achieved complete responses with evorpacept plus R2. 2. This combination shows higher efficacy compared to historical 50% CR rate. 3. Evorpacept was well-tolerated and demonstrated impressive anti-tumor activity. 4. One-year progression-free survival rate stands at 91%; overall survival rate at 100%. 5. Further evaluation of minimal residual disease is expected from the study.
FAQ
Why Very Bullish?
The significant efficacy results reported for evorpacept indicate a substantial improvement over historical treatments, which could result in increased investor confidence and higher market interest in ALXO. The success in this trial reflects positively on ALXO's development strategy and potential future revenues, similar to how breakthrough therapies have historically inflowed capital and bolstered stock prices.
How important is it?
The article focuses on groundbreaking trial results for ALXO's lead candidate, directly impacting its market potential and stock valuation. The high CR rate and overall survival indicate a compelling therapeutic trend that could catch investor attention.
Why Long Term?
The results from the ongoing trials will likely drive interest in longer-term stock performance as therapeutic candidates advance through clinical phases. Historical data shows that successful trial results can lead to sustained stock price appreciation over time, positioning ALXO for future commercial success.
ALX Oncology Reports Promising Phase 2 Trial Results for Evorpacept in Combination with Standard-of-Care Treatments in Indolent B-cell Non-Hodgkin Lymphoma
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 – ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage biotechnology firm specializing in novel cancer therapies, has announced significant results from a Phase 2 investigator-sponsored trial of evorpacept. This study evaluates the efficacy of evorpacept in combination with established treatments, rituximab and lenalidomide (collectively referred to as R2), for patients diagnosed with indolent B-cell non-Hodgkin lymphoma (iNHL). The findings were highlighted during a poster session at the ASH Annual Meeting 2025 in Orlando, Florida.
Key Findings from the Trial
The results demonstrated that the combination treatment achieved a remarkable 92% complete response (CR) rate among patients with untreated iNHL, significantly exceeding the historical CR rate of approximately 50% for R2 alone. Notably, this regimen not only showcased impressive anti-tumor activity but was also well-tolerated by the participants.
Further highlights include:
- Overall response rate (ORR): 100%
- One-year progression-free survival (PFS): 91%
- One-year overall survival (OS): 100%
- 8% of patients experienced a partial response (PR)
Insights from Company Leadership
Jason Lettmann, Chief Executive Officer of ALX Oncology, expressed enthusiasm about the study's results, stating, “We are excited to see the results of this Phase 2 study in frontline indolent non-Hodgkin lymphoma patients, where the addition of evorpacept added a meaningful benefit over the historical data for the standard-of-care regimen of rituximab and lenalidomide.” He emphasized the relevance of the data, particularly considering the high CD47 expression typical in non-Hodgkin lymphoma cases.
Details of the Clinical Trial
The trial, led by Dr. Paolo Strati from The University of Texas MD Anderson Cancer Center, enrolled 24 patients who had not previously received treatment for iNHL. Of these, 14 had follicular lymphoma, while 10 had marginal zone lymphoma. The study successfully met its primary objective, achieving a best CR rate exceeding 80%, thus demonstrating the efficacy of adding evorpacept to standard therapies.
Further details about the presentation at the ASH 2025 meeting include:
- Presentation Title: A Phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide, and rituximab for high tumor burden indolent B-cell non-Hodgkin lymphoma
- Presenter: Paolo Strati, M.D., Associate Professor of Lymphoma-Myeloma
- Date/Time: December 7, 2025; 8:00 a.m. – 8:00 p.m. EST (poster session viewing); 6:00 p.m. – 8:00 p.m. EST (presentation)
- Location: OCCC - West Halls B3-B4
About ALX Oncology
As a clinical-stage biotechnology company, ALX Oncology (Nasdaq: ALXO) is focused on developing innovative therapies aimed at combating cancer and enhancing patient survival rates. Evorpacept is positioned as a potential foundational therapy in the evolving landscape of immuno-oncology. Additionally, ALX Oncology is advancing its second candidate, ALX2004, a novel EGFR-targeted antibody-drug conjugate, which initiated Phase 1 trials in August 2025.
For further information, visit www.alxoncology.com or follow ALX Oncology on LinkedIn.
Cautionary Note
This release contains forward-looking statements, including anticipated future operations, financial performance, and clinical trial outcomes. These statements inherently involve risks and uncertainties. Actual results may differ materially from those projected. For more details, please refer to ALX Oncology’s filings with the Securities and Exchange Commission (SEC).